BCL2 and cancer: Thus, inhibitors of these anti-apoptotic proteins, such as the Bcl-2 inhibitor ABT-737, may act synergistically with the MiTMAB dynamin inhibitors, broadening their therapeutic potential for the treatment of cancer.